New medicines being victimized, says Cyprus pharma group

6 July 2015

There will be problems in the unimpeded distribution of medicines in the Cyprus market, particularly the availability of new, innovative treatments, following the additional 8.5% cut in the price of pharmaceuticals, the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) announced last week.

“As an industry involved in the research and development of pharmaceuticals, we are not opposed to efforts to reduce prices in the private sector,” said KEFEA president Kyriakos Mikellis, but he noted that companies were very disappointed with the manner in which the specific decision was taken, despite the proposals KEFEA had submitted to the Health Ministry.

Drugmakers trapped as they cannot delete no long marketed drugs from the price list

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK